Background: Opioid-induced respiratory depression (OIRD) is a critical safety concern during ambulatory percutaneous liver tumor thermal ablation. Esketamine has been shown to offer a promising opioid-sparing alternative with the potential to provide respiratory stability benefits. We hypothesize that hepatic hilar nerve block (HHNB) combined with esketamine will reduce the incidence of respiratory depression when compared to HHNB in conjunction with fentanyl in this particular context.Methods: This single-center, prospective, double-blind, randomized controlled trial (RCT) will enroll patients undergoing ambulatory ultrasound-guided percutaneous liver thermal ablation. Patients will be randomly assigned to receive either intravenous esketamine 0.37 mg kg−1 (Intervention group) or intravenous fentanyl 1 μg·kg− (Control group). All subjects will receive a standardized premedication consisting of midazolam 0.03 mg kg−1 IV, followed by ultrasound-guided HHNB.Results and analysis: The primary outcome is the incidence of respiratory depression, defined as SpO2 55 mmHg. Secondary outcomes include the rate of anesthesia success, postoperative pain scores, and the consumption of remedial analgesia at 2, 6, and 24 h post-surgery. Additionally, satisfaction scores from both the sonographer and the patient are considered, along with any adverse events that may occur. The statistical analysis will utilize appropriate parametric/non-parametric tests for continuous data and chi-square/Fisher’s exact tests for categorical data (significance p < 0.05), using SPSS (v20.0) and R (v4.4.3; R Foundation) within the RStudio environment (v2024.12.1 + 563).Conclusion and discussion: This trial aims to provide Level I evidence comparing the respiratory depression risk between esketamine-based and fentanyl-based analgesia during HHNB-guided liver ablation. Should esketamine prove to be demonstrably superior in terms of respiratory safety, HHNB-esketamine has the potential to be a viable treatment option.
Introduction: Insomnia is a prevalent psychiatric disorder that significantly impacts mental and physical health. Emerging evidence suggests that gut microbiota, particularly γ-aminobutyric acid (GABA) producing bacteria, plays a critical role in the microbiome-gut-brain axis (MGBA), influencing sleep and mental states. Electroacupuncture (EA) has been shown to have favorable anti-insomnia effects. This research protocol outlines a randomized controlled trial (RCT) designed to investigate the efficacy of EA in modulating GABA levels via the MGBA to alleviate insomnia.Methods and analysis: The study will use glutamate (Glu) concentrations of p-chlorophenylalanine (PCPA) -induced insomnia rat model to examine whether EA at specific acupoints can increase GABA levels in the brain and plasma by enhancing the abundance of GABA-producing gut bacteria. A second experiment will transplant stool from insomnia rats into germ-free mice to evaluate the causal role of microbiota in insomnia pathology. Primary outcome measures include changes in GABA and Glu levels, data about the open field test, and gut microbiota composition.Discussion: This study will provide insights into the therapeutic mechanisms of EA targeting the MGBA in the treatment of insomnia and contribute to the development of novel therapeutic strategies.Ethics and dissemination: This study has been approved by the Laboratory Animal Center of Xiamen University (No. XMULAC20220100). The study findings will be submitted for publication in peer-reviewed academic journals.
26 October 2023 in Journal of Mechanics in Medicine and Biology
Cervical lymph node (CLN) status is an important factor for the patients with major salivary gland carcinomas (MSGCs) with respect to the surgical methods, prognosis, and recurrence. Our aim is to develop a risk model that incorporates clinicopathological and ultrasound (US) features to predict the cervical lymph node metastasis (CLNM) in MSGCs. Retrospective data were gathered for 111 patients with MSGCs who underwent surgical treatment and US examinations at our institution from January 2016 to December 2022. Their clinicopathological and US data were documented and analyzed. Independent predictors predicting CLNM in MSGCs were screened through univariate and multivariate analysis. The nomogram model were built based on independent predictors using logistic regression. The evaluation of the model's performance was then conducted. The clinicopathological and US factors of patient age, lesion size, US reported CLN-positive, histological type, and histological grade were identified as independent predictors for predicting CLNM in MSGCs. The nomogram model, which integrated these predictive factors, achieved an AUC of 0.923 (95% CI: 0.869 ~ 0.977), demonstrating good predictive performance and calibration. Decision curve analysis and clinical impact curve further confirmed its clinical usefulness. The nomogram model we developed holds the potential to predict CLNM in MSGCs preoperatively, thereby enabling the provision of more precise therapeutic strategies.